The Implantable Brain Computer Interface technology industry must work alongside policy makers to expeditiously establish a sustainable pathway for coverage and access for the patients who need the ...
AL-S Pharma AG, a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the ...
The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase 2b ...
Amydis has received $2.5 million to continue mapping toxic deposits of TDP-43 in retinal tissue and develop an eye test for ALS.
The Astros aren’t dead yet. It felt like the AL West would run through Houston forever. The Astros won seven consecutive ...
"Watching my mom die of ALS was one of the most awful things I’ve gone through. I don’t want my children to see me suffer ...
Eye imaging may help distinguish ALS from Alzheimer’s disease by revealing differences in retinal protein deposits using polarized light.
FOX 5 Atlanta on MSN
Atlanta gala raises millions in the fight against ALS
The InterContinental Buckhead Hotel was filled with a powerful sense of purpose on Saturday, March 14, 2026, as the Muscular Dystrophy Association (MDA) hosted its 19th Annual Night of Hope Gala. The ...
Study results Additional Phase 2 Data of AL-S Pharma's Lead Program AP-101 Further Demonstrate Clinically Meaningful Disease Modification ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results